BioLife Solutions, Inc. provided revenue guidance for 2022. Total revenue for 2022 is expected to range from $159.5 million to $171.0 million, reflecting year-over-year growth of 34% to 44% and organic growth of 28% to 39%. COVID-19 related revenue is expected to account for approximately 8% to 9% of total revenue.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
21.97 USD | -4.44% | +21.99% | +35.20% |
May. 13 | Benchmark Upgrades BioLife Solutions to Buy From Hold With $25 Price Target | MT |
May. 09 | Earnings Flash (BLFS) BIOLIFE SOLUTIONS Posts Q1 Revenue $31.7M, vs. Street Est of $24.9M | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+35.20% | 1.06B | |
-4.72% | 182B | |
+3.96% | 112B | |
-2.93% | 68.58B | |
+6.30% | 51.58B | |
+8.02% | 44.24B | |
+8.31% | 43.65B | |
+26.18% | 32.46B | |
+16.79% | 25.99B | |
+0.57% | 25.61B |
- Stock Market
- Equities
- BLFS Stock
- News BioLife Solutions, Inc.
- BioLife Solutions, Inc. Provides Revenue Guidance for 2022